Patient-centered care necessitates a careful consideration of the pharmacokinetic and pharmacodynamic differences between DOACs, and how these relate to individual patient circumstances. Prescribers should be aware of the potential for pharmacokinetic drug interactions with DOACs which may influence prescribing decisions in patients with multiple comorbidities. In order to give an appropriate dose of DOAC drugs, accurate estimation of renal function using the Cockcroft-Gault formula using actual body weight is necessary. An increasing body of evidence supports the use of DOACs in patients who are obese, and this is becoming more routine in clinical practice.
David Seiffge, Maurizio Paciaroni, Duncan Wilson, Masatoshi Koga, Kosmas Macha, Manuel Cappellari, Sabine Schaedelin, Clare Shakeshaft, Masahito Takagi, Georgios Tsivgoulis, Bruno Bonetti, Bernd Kallmünzer, Shoji Arihiro, Andrea Alberti, Alexandros A. Polymeris, Gareth Ambler, Sohei Yoshimura, Michele Venti, Leo H. Bonati, Keith W. Muir, Hiroshi Yamagami, Sebastian Thilemann, Riccardo Altavilla, Nils Peters, Manabu Inoue, Tobias Bobinger, Giancarlo Agnelli, Martin M. Brown, Shoichiro Sato, Monica Acciarresi, Hans Rolf Jäger, Paolo Bovi, Stefan Schwab, Philippe Lyrer, Valeria Caso, Ḱazunori Toyoda, David J. Werring, Stefan T. Engelter, Gian Marco De Marchis
María Asunción Esteve‐Pastor, José Miguel Rivera‐Caravaca, Martín Ruiz Ortiz, Javier Muñiz, Inmaculada Roldán‐Rabadán, Déborah Otero, Raquel López‐Gálvez, Ángel Cequier, Vicente Bertoméu, Lina Badimón, Manuel Anguita, Professor Gregory Lip, Francisco Marı́n
Discussion(0)
No comments yet. Be the first to comment.